临床外科杂志 ›› 2023, Vol. 31 ›› Issue (2): 159-163.doi: 10.3969/j.issn.1005-6483.2023.02.019

• 论著 • 上一篇    下一篇

血清可溶性CD105、CC类趋化因子配体20、CC类趋化因子配体5水平与肺癌手术病人预后的关系

  

  1. 210029 南京医科大学附属脑科医院胸科院区呼吸科   
  • 收稿日期:2022-07-01 修回日期:2022-07-01 接受日期:2022-07-01 出版日期:2023-02-20 发布日期:2023-02-20
  • 通讯作者: 林勇,Email:linyong63@163.com

The relationship between serum S-CD105,CCL20 and CCL5 levels and prognosis of patients with lung cancer surgery

  1. Department of Respiratory Medicine,The Affiliated Brain Hospital of Nanjing Medical University,Jiangsu,Nanjing 210029,China
  • Received:2022-07-01 Revised:2022-07-01 Accepted:2022-07-01 Online:2023-02-20 Published:2023-02-20

摘要: 目的 探讨血清可溶性CD105(S-CD105)、CC类趋化因子配体20(CCL20)、CC类趋化因子配体5(CCL5)水平与肺癌手术病人预后的关系。方法 选取2018年3月~2019年3月于本院接受根治术治疗的86例肺癌病人为观察组,术后随访至2022年3月,根据病人是否复发或死亡分为预后良好组(54例)与预后不良组(32例),同期选取43例健康体检者为对照组。对比S-CD105、CCL20、CCL5水平,观察S-CD105、CCL20、CCL5不同水平的复发率、转移率及术后180天后死亡率;采用Kendall's tau-b法分析SCD105、CCL20、CCL5与肺癌手术病人预后的相关性;采用二元Logistic回归模型分析SCD105、CCL20、CCL5对肺癌手术病人预后影响;采用ROC曲线模式分析S-CD105、CCL20、CCL5预测肺癌手术病人预后的AUC值、敏感度、特异度。结果 观察组的S-CD105为(4.55±0.86)ng/ml、CCL20为(71.97±13.69)ng/ml和CCL5为(49.50±5.17)ng/ml,对照组分别为(3.38±0.52)ng/ml、(53.52±7.52)ng/ml和(17.52±2.02)ng/ml,两组比较差异有统计学意义(P<0.05)。在术前、术后30天、90天时点,两组S-CD105、CCL20、CCL5比较,差异无统计学意义(P>0.05);术后180天,预后不良组的S-CD105为(7.85±1.52)ng/ml、CCL20(88.25±19.65)ng/ml和CCL5(54.74±6.96)ng/ml,预后良好组分别为(5.01±1.05)ng/ml、(65.38±11.74)ng/ml和(43.02±4.11)ng/ml,两组比较差异有统计学意义(P<0.05)。血清S-CD105、CCL20、CCL5高表达组的复发率、转移率及术后180天后死亡率高于低表达组(P<0.05)。二元Logistic回归分析显示,SCD105、CCL20、CCL5水平是影响肺癌手术病人预后的危险因素(P<0.05)。 Kendall's taub相关性分析显示,SCD105、CCL20、CCL5与肺癌手术病人预后呈负相关(r=-0.606、-0.437、-0.619,P<0.05)。ROC曲线分析显示,血清SCD105、CCL20、CCL5预测肺癌手术病人预后不良的AUC值分别为0.937、0.817、0.949(P<0.05);敏感度分别为90.60%、50.00%和93.80%;特异度分别为92.60%、100.00%和92.60%。结论 血清S-CD105、CCL20、CCL5水平在肺癌病人中呈高表达,其水平会随着术后复发或转移而发生改变,动态监测其变化有利于为预后评估提供参考。

关键词: 血清可溶性CD105, CC类趋化因子配体20, CC类趋化因子配体5, 肺癌, 根治术, 预后

Abstract: Objective To investigate the relationship between the levels of serum soluble CD105(S-CD105),CC chemokine ligand 20(CCL20) and CC chemokine ligand 5(CCL5) and the prognosis of patients with lung cancer surgery.Methods A total of 86 lung cancer patients who received radical mastectomy in our hospital from March 2018 to March 2019 and were followed up until March 2022 were selected as the research subjects,and were set up as the observation group.They were divided into a good prognosis group(n=54) and a poor prognosis group(n=32).During the same period,43 healthy subjects were selected as the control group.The levels of S-CD105,CCL20 and CCL5 were compared,and the recurrence rate,metastasis rate and mortality of different levels of S-CD105,CCL20 and CCL5 were observed;the binary logistic regression model was used to analyze the effect of SCD105,CCL20 and CCL5 on the prognosis of patients with lung cancer surgery;ROC curve pattern analysis of AUC value,sensitivity and specificity of S-CD105,CCL20 and CCL5 in predicting the prognosis of patients with lung cancer surgery.Results The SCD105[(4.55±0.86) ng/ml],CCL20[(71.97±13.69)ng/ml] and CCL5[(49.50±5.17)ng/ml] in the observation group were higher than those in the control group [(3.38±0.52) ng/ml,(53.52) ±7.52) ng/ml,(17.52±2.02) ng/ml](all P<0.05).There was no significant difference in S-CD105,CCL20 and CCL5 between the two groups before surgery,30-d and 90-d after surgery(P>0.05).At 180 days after operation,the S-CD105[(7.85±1.52) ng/ml],CCL20[(88.25±19.65) ng/ml] and CCL5[(54.74±6.96) ng/ml] in the poor prognosis group were higher than those in the good prognosis group [(5.01±1.05) ng/ml,(65.38±11.74) ng/ml,(43.02±4.11) ng/ml(all P<0.05).The recurrence rate,metastasis rate and mortality rate of serum S-CD105,CCL20,CCL5 high expression group were higher than those of low expression group(P<0.05).Binary Logistic regression analysis showed that the levels of SCD105,CCL20 and CCL5 were risk factors affecting the prognosis of patients with lung cancer surgery(P<0.05).Kendall's tau-b correlation analysis showed that SCD105,CCL20,and CCL5 were negatively correlated with the prognosis of patients with lung cancer surgery(r=-0.606,-0.437,-0.619,P<0.05).ROC curve analysis showed that the AUC values of serum SCD105,CCL20,and CCL5 for predicting poor prognosis in patients with lung cancer surgery were 0.937,0.817,0.949(P<0.05);the sensitivities were 90.60%,50.00%,and 93.80%,respectively;the specificities were 92.60%,100.00%,92.60%.Conclusion Serum levels of S-CD105,CCL20,and CCL5 are highly expressed in lung cancer patients,and their levels will change with postoperative recurrence or metastasis.Dynamic monitoring of their changes is helpful to provide an important reference for prognosis evaluation.

Key words: serum soluble CD105, CC chemokine ligand 20, CC chemokine ligand 5, lung cancer, radical resection, prognosis

[1] 厉爽 郑波 江斌 朱毓豪. 右半结肠根治术后十二指肠憩室穿孔一例[J]. 临床外科杂志, 2023, 31(2): 175-176.
[2] 刘炯 汪向飞 江斌. 腹腔镜辅助远端胃癌根治术不同Uncut Roux-en-y吻合方式对病人的疗效及对肿瘤标志物和预后的影响[J]. 临床外科杂志, 2023, 31(2): 177-180.
[3] 周硕 王振杰 孙万亮 张登勇 鲁正. 高龄结肠癌病人中CDH13的表达变化与临床及预后相关性研究[J]. 临床外科杂志, 2023, 31(2): 181-184.
[4] 吴智明 蒋磊 叶晟劼 赵文宇. 单孔胸腔镜在磨玻璃结节为主的早期肺癌手术切除中的应用效果研究[J]. 临床外科杂志, 2023, 31(1): 53-56.
[5] 周岩冰. 机器人和4K腹腔镜在胃癌根治术中淋巴结清扫的比较[J]. 临床外科杂志, 2022, 30(9): 819-822.
[6] 蔺金军 刘俊华 慕立峰 黄占有 魏军龙 李永梅. 胃癌手术、介入化疗后存活19年一例[J]. 临床外科杂志, 2022, 30(9): 828-829.
[7] 莫波 王佩 童宜欣 何志军 梁俊 郝志楠. 膜解剖技术在胃癌根治术中应用的效果分析[J]. 临床外科杂志, 2022, 30(9): 835-838.
[8] 薛志有 倪志海 张毅. 胃癌组织中维甲酸相关孤儿受体α、微管相关蛋白轻链3的表达与病人远期预后的关系[J]. 临床外科杂志, 2022, 30(9): 839-843.
[9] 季金涛 康波 苏燕胜. 前列腺特异性膜抗原与前列腺癌Gleason评分的相关性分析及在早期诊断及预后中的价值[J]. 临床外科杂志, 2022, 30(9): 885-888.
[10] 邓朝强 张宁 傅方求 张扬 陈海泉. 肺癌微创3.0的再认识和实践[J]. 临床外科杂志, 2022, 30(8): 701-704.
[11] 陈健 朱余明. 非小细胞肺癌术后辅助治疗研究进展[J]. 临床外科杂志, 2022, 30(8): 707-713.
[12] 倪恒 周春琳 王莺 俞豪杰 王延烨 吕望 胡坚. 中央型肺癌机器人袖式肺叶切除进展及前景展望[J]. 临床外科杂志, 2022, 30(8): 714-717.
[13] 刘凯 李勃 吴向天 明怀德. 二甲双胍通过LncRNA-H19抑制非小细胞肺癌A549迁移及侵袭的机制研究[J]. 临床外科杂志, 2022, 30(8): 719-721.
[14] 牛磊 霍承瑜 刘宗志 王兵. 两种入路单孔胸腔镜下肺叶切除术对非小细胞肺癌病人术后康复进程、肺功能及内环境指标的影响[J]. 临床外科杂志, 2022, 30(8): 722-726.
[15] 李新 盖慧荣 宋蕾 张忠法. 长链非编码RNA SRGAP3-AS2异常表达通过Janus激酶信号调节非小细胞肺癌侵袭和迁移[J]. 临床外科杂志, 2022, 30(8): 727-730.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 夏雨佳, 左维维, 王梦园, 胡明. 亚甲基蓝在胃肠道恶性肿瘤淋巴结检获中应用价值的Meta分析[J]. 临床外科杂志, 2020, 28(1): 59 -62 .
[2] 孙志鹏 吴广东 王良 束斌 黄鑫 王鹏飞 项灿宏. 2022美国国立综合癌症网络临床实践指南:壶腹部腺癌诊疗解读[J]. 临床外科杂志, 2023, 31(1): 4 -6 .
[3] 蓝儒竹. 男科疾病诊疗新进展[J]. 临床外科杂志, 2023, 31(2): 101 -102 .
[4] 彭靖. 男性不育症诊断和治疗的热点问题[J]. 临床外科杂志, 2023, 31(2): 102 -105 .
[5] 刘晓强 李岳铮 张昊 王尚任. 人工智能在男科疾病中的应用[J]. 临床外科杂志, 2023, 31(2): 106 -108 .
[6] 李彦锋. 血精的病因学诊断及规范化处理[J]. 临床外科杂志, 2023, 31(2): 109 -112 .
[7] 张炎. 射精功能障碍[J]. 临床外科杂志, 2023, 31(2): 113 -117 .
[8] 李健瑛 李铮 赵福军. 男性勃起功能障碍的诊疗进展[J]. 临床外科杂志, 2023, 31(2): 117 -121 .
[9] 丁大帅 廖敏 王锋 毛振 郭天旺 宋勇波. 成人重度肾积水肾穿刺造瘘术肾盂引流液蛋白水平与肾功能关系[J]. 临床外科杂志, 2023, 31(2): 122 -126 .
[10] 管富勇 王黎 王俊霖 姚启盛. 非肌层浸润性膀胱癌经尿道膀胱肿瘤电切术后肿瘤残余病人行二次电切术后复发的危险因素分析[J]. 临床外科杂志, 2023, 31(2): 127 -131 .